Feedback
Settings

Settings

Goto Application

1. WO2021247925 - STRUCTURE-GUIDED IMMUNOTHERAPY AGAINST SARS-COV-2

Submit observation
PermaLink
Publication Number WO/2021/247925
Publication Date 09.12.2021
International Application No. PCT/US2021/035782
International Filing Date 03.06.2021
IPC
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applicants
  • VIR BIOTECHNOLOGY, INC. [US]/[US]
  • UNIVERSITY OF WASHINGTON [US]/[US]
  • HUMABS BIOMED SA [CH]/[CH]
  • CORTI, Davide [IT]/[CH]
  • SNELL, Gyorgy [US]/[US]
  • CZUDNOCHOWSKI, Nadine [DE]/[US]
  • VEESLER, David [FR]/[US]
  • WALLS, Alexandra C. [US]/[US]
  • PARK, Young-Jun [KR]/[US]
  • TORTORICI, M. Alejandra [US]/[US]
Inventors
  • CORTI, Davide
  • SNELL, Gyorgy
  • CZUDNOCHOWSKI, Nadine
  • VEESLER, David
  • WALLS, Alexandra C.
  • PARK, Young-Jun
  • TORTORICI, M. Alejandra
Agents
  • MORGAN, John, A.
  • OBEIDAT, Baha, A.
  • ADRA, Bilal H.
  • KUMABE, Blake, K.
  • SAHACHARTSIRI, Bobby
  • SOLTANI, Bobby, B.
  • ZENTZ, Bradley, J.
  • SARGEANT, Brooke
  • QUIST, Brooke, W.
  • ROTH, Carol, J.
  • EIDT, Chandra, E.
  • O'BRIEN, Daniel
  • CARLSON, David, V.
  • CONLEE, David, C.
  • STARK, Duncan
  • TARLETON, E., Russell
  • SUN, Eileen, S.
  • HARWOOD, Eric, A.
  • GERTZ, Glenda, A.
  • HAN, Hai
  • TALBERT, Hayley, J.
  • KHANNA, Hemant
  • BARRETT, Jared, M.
  • DANLEY, Jeffrey, E.
  • SAKOI, Jeffrey, M.
  • SEO, Jeong Hee
  • BAUNACH, Jeremiah, J.
  • ZHANG, Jianping
  • WAKELEY, John, J.
  • COE, Justin, E.
  • HENCKEL, Karen, M.
  • HEFTER, Karl, A.
  • HERMANNS, Karl, R.
  • MORGAN, Kevan, L.
  • COSTANZA, Kevin, S.
  • COOPER, Michael, P.
  • LECOINTE, Michelle M.
  • BENDEMIRE, Paul, D.
  • LIN, Qing
  • HALLER, Rachel, A.
  • WEBB, Samuel, E.
  • LIU, Shi
  • LEEK, Shoko, I.
  • ROSENMAN, Stephen, J.
  • LAWRENZ, Steven, D.
  • ABEDI, Syed
  • SHEWMAKE, Thomas, A.
  • BOLLER, Timothy, L.
  • LIGON, Toby, J.
  • LI, Yiheng
  • SAKOI, Zachary, M.
Priority Data
63/034,32603.06.2020US
63/055,86123.07.2020US
63/058,36829.07.2020US
63/066,09314.08.2020US
63/070,80326.08.2020US
63/078,15714.09.2020US
63/166,87426.03.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) STRUCTURE-GUIDED IMMUNOTHERAPY AGAINST SARS-COV-2
(FR) IMMUNOTHÉRAPIE GUIDÉE PAR UNE STRUCTURE DIRIGÉE CONTRE LE SARS-COV-2
front page image
Abstract
(EN) The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind in certain regions of a SARS-CoV-2 S glycoprotein and can neutralize a SARS-CoV-2 infection. Also provided are immunogenic compositions that comprise a SARS-CoV-2 S glycoprotein or a portion thereof that is capable of being bound by an antibody or antigen-binding fragment.
(FR) La présente invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui peuvent se lier dans certaines régions d'une glycoprotéine S du SARS-CoV-2 et peuvent neutraliser une infection par le SARS-CoV-2. L'invention concerne également des compositions immunogènes qui comprennent une glycoprotéine S du SARS-CoV-2 ou une partie de celle-ci qui peut être liée par un anticorps ou un fragment de liaison à l'antigène.
Latest bibliographic data on file with the International Bureau
# -